Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis

Li, Maolan, Liu, Fatao, Zhang, Fei, Zhou, Weiping, Jiang, Xiaoqing, Yang, Yuan, Qu, Kai, Wang, Yueqi, Ma, Qiang, Wang, Ting, Bai, Lu, Wang, Zheng, Song, Xiaoling, Zhu, Yidi, Yuan, Ruiyan, Gao, Yuan, Liu, Yongchen, Jin, Yunpeng, Li, Huaifeng, Xiang, Shanshan, Ye, Yuanyuan, Zhang, Yijian, Jiang, Lin, Hu, Yunping, Hao, Yajuan, Lu, Wei, Chen, Shili, Gu, Jun, Zhou, Jian, Gong, Wei, Zhang, Yong, Wang, Xuefeng, Liu, Xiyong, Liu, Chang, Liu, Houbao, Liu, Yun, Liu, Yingbin·2019·Gut

Abstract

Objectives: Patients with gallbladder carcinoma (GBC) lack effective treatment methods largely due to the inadequacy of both molecular characterisation and potential therapeutic targets. We previously uncovered a spectrum of genomic alterations and identified recurrent mutations in the ErbB pathway in GBC. Here, we aimed to study recurrent mutations of genes and pathways in a larger cohort of patients with GBC and investigate the potential mechanisms and clinical significance of these mutations. Design: We performed whole-exome sequencing (WES) in 157 patients with GBC. Functional experiments were applied in GBC cell lines to explore the oncogenic roles of ERBB2 / ERBB3 hotspot mutations, their correlation with PD-L1 expression and the underlying mechanisms. ERBB inhibitors and a PD-L1 blocker were used to evaluate the anticancer activities in co-culture systems in vitro and in vivo. Results: WES identified ERBB2 and ERBB3 mutations at a frequency of 7%–8% in the expanded cohort, and patients with ERBB2 / ERBB3 mutations exhibited poorer prognoses. A set of in vitro and in vivo experiments revealed increased proliferation/migration on ERBB2 / ERBB3 mutation. Ectopic expression of ERBB2/ERBB3 mutants upregulated PD-L1 expression in GBC cells, effectively suppressed normal T-cell-mediated cytotoxicity in vitro through activation of the PI3K/Akt signalling pathway and contributed to the growth and progression of GBC in vivo. Treatment with an ERBB2/ERBB3 inhibitor or a PD-L1 monoclonal antibody reversed these immunosuppressive effects, and combined therapy revealed promising therapeutic activities. Conclusions: ERBB2 / ERBB3 mutations may serve as useful biomarkers in identifying patients who are sensitive to ERBB2/ERBB3 inhibitors and PD-L1 monoclonal antibody treatment. Trial registration number: NCT02442414 ;Pre-results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-316039

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 188

Metadata

Authors
Li, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., Qu, K., Wang, Y., Ma, Q., Wang, T., Bai, L., Wang, Z., Song, X., Zhu, Y., Yuan, R., Gao, Y., Liu, Y., Jin, Y., Li, H., Xiang, S., Ye, Y., Zhang, Y., Jiang, L., Hu, Y., Hao, Y., Lu, W., Chen, S., Gu, J., Zhou, J., Gong, W., Zhang, Y., Wang, X., Liu, X., Liu, C., Liu, H., Liu, Y., & Liu, Y.
Venue
Gut
Publisher
BMJ
Published
2018-06-28
Volume
68
Issue
6
Pages
1024-1033
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2811483470
Cited by
188
References
8
FWCI
13.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. https://app.cochat.ai/papers/10.1136/gutjnl-2018-316039
The paper
Li, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., Qu, K., Wang, Y., Ma, Q., Wang, T., Bai, L., Wang, Z., Song, X., Zhu, Y., Yuan, R., Gao, Y., Liu, Y., Jin, Y., Li, H., . . . Liu, Y. (2019). Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. https://doi.org/10.1136/gutjnl-2018-316039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.